Public Protocol
Platform

Case study

FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

External resource. Not made or verified by Public Protocol.

FDA announcement of 8 December 2023 approving Casgevy, its first approved CRISPR/Cas9 therapy, and Lyfgenia for sickle cell disease in patients 12 and older.

Go to the source

https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease

Maintainer
US Food and Drug Administration
Licence, as stated at its source
Not stated on the page opened
Open or commercial
Commercial
Maturity
WorkingOur reading, 16 November 2026
Safety
S3medical
Review
Listed 16 November 2026by Public Protocol editors
Checked
16 November 2026
Next check due
16 May 2027
Steward
Public Protocol editors

Where it sits in the blueprint

Stages

Learn

Context

Climate, setting, scale, cost and skill: not stated in this entry. Check the source against your own place and numbers.

Verification

No verification is recorded on Public Platform for this entry. Records are added when someone reads it for accuracy, reviews it with a stated qualification, builds it or measures it.

Record

How it came in

Seed catalogue, 16 November 2026. Listed from Praecise open research. The source was opened and described on the date shown.

Licence

Not stated on the page opened. Read at https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease. How licences are recorded